Literature DB >> 12106622

Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial.

David B Matchar1, Gregory P Samsa, Stuart J Cohen, Eugene Z Oddone, Annette E Jurgelski.   

Abstract

Randomized trials have indicated that well-managed anticoagulation with warfarin could prevent more than half of the strokes related to atrial fibrillation. However, many patients with atrial fibrillation who are eligible for this therapy either do not receive it or are not maintained within an optimal prothrombin time-international normalized ratio (INR) range. We sought to determine whether an anticoagulation service within a managed care organization would be a feasible alternative for providing anticoagulation care. We performed a multi-site randomized trial in six large managed care organizations in the United States. Subjects were aged 65 years or older and had nonvalvular atrial fibrillation. At each site, physician practices were divided into two geographically defined practice clusters; each site was randomly assigned to have one intervention and one control cluster. The intervention cluster received an anticoagulation service that satisfied specifications for high-quality anticoagulation care and was coordinated through the managed care organization. Control clusters continued with their usual provider-based care. We measured the proportion of time that warfarin-treated patients in each of the clusters (intervention and control) were in the target range for the INR at baseline, and again during a follow-up period. Five of the six selected sites succeeded at developing an anticoagulation service. Patients in the intervention and control clusters had similar demographic characteristics, contraindications to warfarin, and risk factors for stroke. Among patients (n = 144 in the intervention clusters; n = 118 in the control clusters) for whom data were available during the baseline and follow-up periods, the changes in percentages of time in the target range were similar for those in the intervention clusters (baseline: 47.7%; follow-up: 55.6%) and in the control clusters (baseline: 49.1%; follow-up: 52.3%; intervention effect: 5%; 95% confidence interval: -5% to 14%; P = 0.32). Although it was feasible in a managed care organization to implement anticoagulation services that were tailored to local circumstances, provision of this service did not improve anticoagulation care compared with usual care. The effect of the anticoagulation service was limited by the utilization of the service, the degree to which the referring physician supports strict adherence to recommended target ranges for the INR, and the ability of the anticoagulation service to identify and to respond to out-of-range values promptly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12106622     DOI: 10.1016/s0002-9343(02)01131-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  38 in total

1.  Physician attitudes concerning anticoagulation services in the long-term care setting.

Authors:  Leslie R Harrold; Jerry H Gurwitz; Janet P Tate; Richard Becker; Tammy Stuart; Anne Elwell; Martha Radford
Journal:  J Thromb Thrombolysis       Date:  2002-08       Impact factor: 2.300

Review 2.  Role of the anticoagulant monitoring service in 2018: beyond warfarin.

Authors:  Nathan P Clark
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Monitoring anticoagulation in atrial fibrillation.

Authors:  Chaitanya Sarawate; Mirko V Sikirica; Vincent J Willey; Michael F Bullano; Ole Hauch
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

Review 6.  What you should know about the 2008 American College of Chest Physicians evidence-based clinical practice guidelines (8th) on antithrombotic and thrombolytic therapy.

Authors:  Scott Kaatz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

7.  Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France.

Authors:  Marc Ruivard; Christine Berger; Abdellaziz Achaibi; Claude Campagne; Pierre Philippe
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

8.  Novel anticoagulants in atrial fibrillation stroke prevention.

Authors:  Nicholas B Norgard; James J Dinicolantonio; Taylor J Topping; Benjamin Wee
Journal:  Ther Adv Chronic Dis       Date:  2012-05       Impact factor: 5.091

Review 9.  Impact on patient care: patient case through the continuum of care.

Authors:  Scott Kaatz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

10.  Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism.

Authors:  Patrick P Kneeland; Margaret C Fang
Journal:  Patient Prefer Adherence       Date:  2010-03-24       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.